A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

NCT00319332 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study has been cancelled prior to enrollment

Conditions

Lymphoma, Small Cleaved-Cell, Follicular
Lymphoma, Large-Cell, Follicular
Lymphoma, Follicular
Lymphoma, Non-Hodgkin

Interventions

DRUG: Ibritumomab Tiuxetan
DRUG: Iodine I 131 Tositumomab

Sponsor

GlaxoSmithKline